Результаты поиска - Alexander E. Perl

Отмена результатов
  1. 1
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML по Alexander E. Perl

    Опубликовано 2017
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Availability of FLT3 inhibitors: how do we use them?

    Availability of FLT3 inhibitors: how do we use them? по Alexander E. Perl

    Опубликовано 2019
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML по Alexander E. Perl

    Опубликовано 2017
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Gilteritinib: potent targeting of FLT3 mutations in AML

    Gilteritinib: potent targeting of FLT3 mutations in AML по Mark J. Levis, Alexander E. Perl

    Опубликовано 2020
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  5. 5
    Advances in patient care through increasingly individualized therapy

    Advances in patient care through increasingly individualized therapy по Courtney D. DiNardo, Alexander E. Perl

    Опубликовано 2019
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  6. 6
    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemothera... по Alexander E. Perl, Margaret Kasner, Doris Shank, Selina M. Luger, Martin Carroll

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia по Pamela J. Sung, Mayumi Sugita, Holly K. Koblish, Alexander E. Perl, Martin Carroll

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib по Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations по Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith

    Опубликовано 2020
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study по Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome по Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Опубликовано 2013
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia по Christine M. McMahon, Jonathan Canaani, Bryan Rea, Rachel L. Sargent, Julianne Qualtieri, Christopher D. Watt, Jennifer J.D. Morrissette, Martin Carroll, Alexander E. Perl

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia

    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia по Hagop M. Kantarjian, Nicholas J. Short, Courtney D. DiNardo, Eytan M. Stein, Naval Daver, Alexander E. Perl, Eunice S. Wang, Andrew H. Wei, Martin S. Tallman

    Опубликовано 2021
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  14. 14
    A robust xenotransplantation model for acute myeloid leukemia

    A robust xenotransplantation model for acute myeloid leukemia по P V Sanchez, Robin Perry, Jean‐Emmanuel Sarry, Alexander E. Perl, Kathleen M. Murphy, Cezary Swider, Adam Bagg, John Choi, Jaclyn A. Biegel, Gwenn Danet-Desnoyers, Martin Carroll

    Опубликовано 2009
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML по Jorge E. Cortés, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220

    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220 по Panpan Hou, Chao Wu, Yuchen Wang, Rui Qi, Dheeraj Bhavanasi, Zhixiang Zuo, Cédric Dos Santos, Shuliang Chen, Yu Chen, Hong Zheng, Hong Wang, Alexander E. Perl, Deyin Guo, Jian Huang

    Опубликовано 2017
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations по Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason E. Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL по Christian Hurtz, Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li, Asen Bagashev, Bryan Manning, Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML по Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    Опубликовано 2012
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) по Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: